The present invention provides a Lactobacillus composition and a use thereof for improving anxiety caused by antibiotics, wherein the Lactobacillus composition comprises Lactobacillus plantarum GMNL-141, Lactobacillus rhamnosus GM-020, Lactobacillus acidophilus GMNL-185, or a combination thereof. The Lactobacillus composition can effectively improve imbalance of an individual's intestinal flora caused by antibiotics to help stabilize and increase species richness and increase the synthesis of mood-stabilizing compounds, including flavonoids, flavonols, isoquinoline alkaloids, niacinamide, nicotinamide, and short-chain fatty acids in intestine, and thus effectively improve antibiotic-induced with anxiety disorders.

A preparation comprising probiotic strains belonging to the genera Bacillus sp., Lactobacillus sp., optionally Pediococcus sp. as viable cells or cytoplasmic extract thereof, and proteases, wherein the strains can degrade peptide sequences of gliadins. The preparation can be used to produce gluten-free foods from gluten-containing cereals or to treat gluten-related disorders.

The invention relates to plasmids capable of expressing a protein targeting immune cells when transformed into a lactic acid bacterial cell, wherein the protein is chosen from the group consisting of murine and human CXCL12 1α; CXCL17 and Ym1. The invention further relates to lactic acid bacteria transformed with a said plasmid, as well as the use of said lactic acid bacteria for wound healing in humans and animals.

The present invention relates to a culture or kit-of-part comprising a Lactobacillus delbrueckii subsp lactis strain, and uses thereof to manufacture a cereal-based lactic acid-fermented product, in particular a maize-based lactic acid-fermented product such as mahewu.

The present invention is related to a method of reducing tobacco addiction in a smoking subject with Lactobacillus fermentum GKF3, including daily administering an oral composition containing the Lactobacillus fermentum GKF3 to the smoking subject, in which the oral composition reduces the total amount of the nicotine metabolites in urine.

A strain of Lactobacillus crispatus KBL693 and the use thereof are disclosed. The strain of Lactobacillus crispatus KBL693 (Accession No. KCTC 13519BP) attenuates allergic reactions of cells, significantly improves symptoms of atopic dermatitis, and exhibits anti-inflammatory and anti-fungal effects. Thus, the single strain alone can achieve all the purposes of alleviating atopic dermatitis and other allergic diseases and improving inflammatory diseases and autoimmune diseases, thereby finding advantageous applications as a probiotic substance. In addition, the strain, based on the anti-fungal activity thereof, can be advantageously utilized in a skin external preparation against various skin diseases caused by fungi, and in a cosmetic composition and a functional patch for alleviating sensitive skin.

The invention discloses a Schleiferilactobacillus harbinensis (former name Lactobacillus harbinensis) M1 and use thereof. The preservation number of Schleiferilactobacillus harbinensis M1 is GDMCC No. 60305. The strain is sensitive to antibiotics such as ampicillin, tetracycline and chloramphenicol, and its safety meets the requirements of EFSA. Its supernatant has a significant inhibitory effect on Listeria monocytogenes, Streptococcus hemolyticus and Staphylococcus aureus. The present invention also protects the use of Schleiferilactobacillus harbinensis M1 in fermented soymilk; using the bacteria to ferment soymilk alone has the advantages of strong acid production ability, high amount of viable bacteria, few or even completely no beany flavor substances, and significant higher content of characteristic aroma components of fermented milk, which greatly improves the sensory flavor of fermented soymilk.

Fermented milk products can provide multiple benefits. However, it was commonly believed that fermented milk products are not suitable for the administration to canids as e.g. dogs can be intolerant to lactose. The present invention provides fermented milk products for administration to canids.

The present invention is intended to provide a lactic acid bacterium-containing composition that is effective for suppression of the onset of allergies. More specifically, the present invention relates to a composition comprising lactic acid bacteria belonging to Lactobacillus animalis, wherein the composition is provided in the form of, for example, a food or beverage composition, a pharmaceutical composition, a feed composition, a sanitary composition or the like. Furthermore, the present invention provides a method for preventing the onset of allergies.

Bacterial strains including B. breve BbIBS01 (DSM 33231), B. breve BbIBS02 (DSM 33232), B. animalis subsp. lactis BIIBS01 (DSM 33233) and L. plantarum LpIBS01 (DSM 33234) are described. Furthermore, compositions are further described comprising a mixture of at least one or more of the aforementioned bacterial strains and, optionally, at least one further bacterial strain, selected from a bacterial strain L. casei DG® (CNCM I-1572) and bacterial strain L. paracasei LPC-S01™ (DSM 26760) and related method for the treatment of gastrointestinal diseases, disorders or symptoms, in particular functional gastrointestinal disorders, such as, irritable bowel syndrome (IBS).